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Abstract
England and Wales are moving toward a model of ‘opt out’ for use of personal
confidential data in health research. Existing research does not make clear how
acceptable this move is to the public. While people are typically supportive of health
research, when asked to describe the ideal level of control there is a marked lack of
consensus over the preferred model of consent (e.g. explicit consent, opt out etc.).
This study sought to investigate a relatively unexplored difference between the
consent model that people prefer and that which they are willing to accept. It also
sought to explore any reasons for such acceptance.
A mixed methods approach was used to gather data, incorporating a structured
questionnaire and in-depth focus group discussions led by an external facilitator. The
sampling strategy was designed to recruit people with different involvement in the
NHS but typically with experience of NHS services. Three separate focus groups were
carried out over three consecutive days.
The central finding is that people are typically willing to accept models of consent
other than that which they would prefer. Such acceptance is typically conditional
upon a number of factors, including: security and confidentiality, no inappropriate
commercialisation or detrimental use, transparency, independent overview, the
ability to object to any processing considered to be inappropriate or particularly
sensitive.
This study suggests that most people would find research use without the possibility
of objection to be unacceptable. However, the study also suggests that people who
would prefer to be asked explicitly before data were used for purposes beyond
direct care may be willing to accept an opt out model of consent if the reasons for
not seeking explicit consent are accessible to them and they trust that data is only
going to be used under conditions, and with safeguards, that they would consider
to be acceptable even if not preferable.
Keywords: Personal confidential data; Health research; Opt out; Explicit consent;
Patient preference; Public attitude
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Background
The governance of research access to information in health records is changing in
England and Wales. The Health and Social Care Act 2012 has created new powers to
mandate the disclosure of personal confidential dataa (PCD) from health care professionals
to support indirect care purposes, including health research.b The law allows for the man-
dated disclosure of confidential patient information, from health care professionals, with
no requirement for patient consent or opportunity for patient objection. In fact, notwith-
standing the formal legal position, the Secretary of State for Health has undertaken to
ensure that patient objection is respected in practice.c This effectively moves toward a
national ‘opt out’ model for much health research using PCD extracted from individual
health records and processed within the Health and Social Care Information Centre.
Qualitative and quantitative research conducted on patient attitudes has consistently
found individuals to be broadly supportive of health records being used for research pur-
poses. At the same time people also frequently express a preference for being asked before
PCD is disclosed by health professionals for purposes beyond direct care.d When pressed
to choose between alternative consent models, for example between opt in or opt out, the
picture reported has been fragmented. Opinion has been broadly divided across a range of
possible consent models. However, within that broad spectrum of views there has been
consistent support by some for disclosure only with explicit consent. A study by the
Department of Health found that “about half of the general public (53%) and patients
(46%) thought that identifiable data should never be used without consent”e and a meta-
study of different published papers concluded that
“there was no consensus on a preferred model either within or across studies, although
participants often considered the balance of obtaining consent against the public benefit
incurred by unrestricted research. Despite this recognition, many participants maintained
that informed consent should always be sought, out of respect for the individual”.f
This might lead one to query the extent to which the move to increasingly adopt an ‘opt
out’ model of consent in England and Wales is acceptable to the public in general. The
authors of the meta-study, Hill et al., noted that,
“[a]lthough researchers may wish for easier access to medical records to reduce potential
bias and the cost of the consent process, public opinion may not be so permissive”.g
This most recent meta-study also confirmed studies reporting consistently low levels of
public awareness of the research that takes place using health records and the difficulties
presented to certain kinds of research if explicit consent is a requirement.h Hill et al’s
response was to investigate whether providing individuals with information about the
research process, and the problems of selection bias (that can be associated with seeking
explicit consent to the use of PCD) altered people’s views about the necessity of consent.
They found that
“following discussion about selection bias, participant’s views about research without
consent became more favourable, with some men changing their opinion and no
longer stating the need for informed consent. However, a small minority remained
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adamant that they always want an opportunity to consent or at least to have an opt out
consent option”.i
The result is encouraging for those who favour ‘opt out’ as a model of consent. It does
underline the importance of people being informed about the reasons for adopting ‘opt out’
as a model rather than ‘opt in’. It suggests that amongst those who have expressed a
preference for explicit consent there are a number who would be willing to switch their
preference if they were clearer on the benefits of doing so for health research. It is also
possible that there is a fraction that would continue to want explicit consent, and if they
were asked would continue to indicate opt in to be their preferred model, but would
nevertheless accept there to be good reason for ‘opt out’ – at least in certain circumstances.
The idea that people might recognise a distinction between what they would ideally
prefer to happen and what they would be willing to accept, given the costs associated with
real-world alternatives, is relatively unexplored in the literature. Although studies to date
have found a fragmented picture when investigating which models of consent members of
the public want, it might be that broader levels of agreement could be found if the
question of acceptability were to be explicitly disengaged within investigations from the
question of preference.
Moreover, understanding what informs acceptance (of a lower level of individual control
than would ideally be preferred) by members of the public will – assuming there is a
desire for such access to be as widely acceptable to the public as possible – inform
development of the criteria of access (without explicit consent). It is also relevant to which
conditions and safeguards are highlighted within any campaign to raise public awareness,
and presumably acceptance, of research use of PCD without explicit patient consent.j
Objectives
The research had two key objectives. First, to establish whether there is in fact a difference
between the level of individual control over access to confidential patient data for health
research purposes that people are willing to accept, given the implication of exercising
different levels of control for the possibilities of health research, and the level that they
would ideally prefer and express as their first choice. Second, if there is a difference, then
to understand why people might be willing to accept a different level of control to that
which they prefer. Associated with this second objective is understanding what condi-
tions, if any, influence the acceptability of different trade-offs between individual control
and health research access to PCD contained within individual health records. This was a
pilot study and it was not intended that the results be generalizable. The objective was to
test the idea that there might be a difference between preference and acceptance and to
begin to explore the potential reasons for any such difference.
Methods
This was a pilot study to explore the reasons that people might give for preferring, and
for accepting, different trade-offs between individual control and access for health
research purposes: The higher the level of individual control over research access, then
the more difficult it can be to conduct certain kinds of health research. A mixed methods
approach was used to gather data, incorporating a structured questionnaire and in-depth
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focus group discussions led by an external facilitator. A focus group approach was
adopted because it suited the aims of the research; at this pilot stage we were simply
seeking to explore individual attitudes and to unpack the concepts of acceptability and
preference regarding any unavoidable ‘trade-off ’ between the public good of a confidential
health service and the public good of health research.
The study was designed and delivered at the University of Sheffield. It involved focus
groups with members drawn from active patient or PPI (public and patient involvement)
communitiesk and also from the general university population. The intention was to
establish, at an early stage, whether or not there is a difference between the level of
individual control that people would prefer and the level that they would be willing to
accept if it facilitated (conditional) access to personal confidential data for health research
purposes. Also, to consider, if there was a difference, what reasons people might offer for
accepting different trade-offs between access and privacy.
Sample
The sampling strategy was designed to include people with different levels and kinds of
involvement in the National Health Service (NHS) and/or health research. Three separate
focus groups were planned over three consecutive days; this was deemed an appropriate
number given that it was a pilot study and exploratory in nature. We were also operating
within time and funding restraints.
Groups 1 and 2 were recruited via a PPI Facilitator for the South Yorkshire
Comprehensive Local Research Network (SYCLRN). Email invitations were sent by the
PPI Facilitator, using email addresses already held or publicly available, to leaders of
established patient groups with a request that the invitations were passed on to their
members. If contact details of members were publicly available, then the facilitator also
contacted group members directly and invited them to take part. Groups contacted
were all local to the area to keep travel costs low. The Facilitator was asked to continue
to recruit until there were at least 7 members in each of these two groups (in fact, 10
were recruited).
Individuals for Group 3 were recruited by generic internal email to students and staff of
The University of Sheffield. The invitation was electronically signed by the Principal
Investigator (PI), who is employed by the university, although it was sent via central
university administration. There was a high response to the query and 10 people (5 staff
and 5 students) were invited to participate on a ‘first-come’ basis.
It was expected that members of Groups 1 and 2 would have experience of the NHS
that would result in those groups collectively having ‘above average’ involvement. It was
hoped that members of Group 3 would respond to the invitation only due to an interest
in the issues to be discussed but that members of Group 3 would have what might be
described as ‘average’ levels of prior involvement with the NHS. This would have offered
an interesting point of comparison between the three groups. However, numbers were
always going to be too low to make any claims about views being representative of
particular sections of the public or patient populations. In the event, members of Group 3
expressed prior levels of involvement that also might be described collectively as ‘above
average’. The results of this work are not presented as generalizable to the public in
general nor to any particular section of the public or patient community. This needs to be
kept in mind when interpreting the results and their significance.
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Although a person’s level of involvement was not treated as a variable for the purposes of
analysis, it is relevant to know what people’s prior involvement was as it helped to
contextualise their discussion. Each member of a focus group was invited to briefly explain,
in a non identifiable way, the nature and kind of involvement that they previously had with
the NHS. These descriptions were transcribed and are reported within the results section.
Focus groups
Each of the different groups was scheduled from 10.30 am to 2.00 pm with a break for
lunch. When people arrived on the day, they were asked to sign a written consent form.
Participants were informed that discussion would be audio-recorded and transcribed. It
was made clear that no identifiable information would be reported.
From 10.30 am to 12.00 participants were given background information about the
legality of use of confidential patient information for research purposes without patient
consent and the significance of the concept of public interest for decisions about such
use. They were introduced to different concepts of public interest and were introduced to
the idea that one conception of public interest would insist that any trade-off between
common interests in confidentiality and health improvement was for reasons that the
public would find accessible and acceptable. Participants were then given a simple
questionnaire, in the form of a table, to complete and we broke for lunch.
After lunch, participants were invited to explain and discuss their preferred idea of
public interest and their ranking of alternative trade-offs between individual control and
access for health research purposes. An exploratory qualitative approach was adopted to
elicit the concerns or issues raised by people in relation to alternative trade-offs.
Questions were asked by the facilitator to prompt discussion of preferences and to
question the relationship between preferred level of control and the level(s) of control that
was considered to be acceptable. The discussion was lively in each group and
conversation was generally allowed to flow with intervention only to prompt participants
to clarify responses, to challenge an individual to provide reasons for a position, or to offer
an alternative view for the sake of stimulating the discussion. At the end of the discussion,
participants were asked to repeat completion of the questionnaire so that any shift in
opinion could be identified. The questionnaires, which contained separate columns for
morning and afternoon responses, were returned anonymously at the end of the day and
marked only with group number for the purposes of comparative analysis.
Questionnaire
The questionnaire asked participants to rank in order of preference (1 =most preferred, 4 =
least preferred) four consent models to control access to patient confidential data (PCD)
for health research purposes, each representing a different trade-off between individual
control over access to PCD and the facilitation of health research. For the purposes of the
discussion PCD was described as an individual’s identifiable health information. The four
models are summarised in Table 1.
In addition to ranking these four options in order of preference, participants were also
asked to indicate in a separate column whether they considered each of the alternatives to
represent either an acceptable or unacceptable trade-off between individual control and
access for health research purposes. They were asked to put a “Y” next to each alternative
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that they considered to be acceptable (regardless of how they had ranked it in order of
preference) and “N” next to each alternative that they considered to be unacceptable
(again regardless of any order of preference).
Analysis
The quantitative data from the questionnaires were recorded and analysed using SPSS.m
One-way frequency tables were used for descriptive analysis of the key concepts and
bivariate analysis was conducted using 2×2 contingency tables. All variables were
nominative/ordinal and the appropriate non-parametric statistical tests were selected. For
the qualitative data, the de-identified transcripts were inputted into the Nvivon software
package immediately after the focus group sessions by the PI. The transcripts were coded
and a process of thematic analysis used to identify emergent themes, patterns and extract-
ing any particularly cogently expressed opinions on different issues (Crow and Semmens
2008). The coding was carried out by two coders independently (the authors) and then
the emergent themes were compared and refined in discussion. In total, 40 coded themes
were finally agreed upon.
Results
In total, 28 of the 30 invited participants turned up and took part in the focus groups.
One person gave their apologies in advance and one person did not contact the research
team to offer explanation for non-attendance.
Each of the three groups was different in terms of their level of experience with the
NHS. Gender but neither age nor ethnicity was recorded for each participant. Prior
experience of the NHS or research involving NHS records was described by participants
in their own words, in a non-identifiable way, at the beginning of the session.
Group 1 (Tuesday, n = 9) was a mixed group consisting of 8 women and 1 man. They
included a member of a local consumer research panel for cancer; 2 carers (one with
extensive experience of caring for mental health); 2 previous members of Community
Health Councils (one of whom was a previous Health Researcher and the other of whom
was a member of PPI Group); a member of a Health Panel; a Patient Advocate on
Research Groups and REC member; a researcher with experience of using patient data
and one other who self-described as ‘involved with cancer research’.
Group 2 (Wednesday, n = 10) comprised of people with primary care involvement. It
included 8 people who sat on GP practice or local area patient participation group (3 of
whom were now involved with a local CCG; 1 of whom indicated previous research
experience; and 2 of whom were also involved in local quality assurance). In addition, one
Table 1 Four models of personal confidential data disclosure for health research
Model Description
Model 1 Information should be disclosed without explicit consent and with no opt out
Model 2 Information should be disclosed without explicit consent but with opt out permitted
for sufficient reasonl
Model 3 Information should be disclosed without explicit consent but with opt out permitted
for any reason
Model 4 Information should be disclosed only with explicit consent
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member reported involvement in the local quality assurance of out of hours GP services
and one member reported involvement with both local CCG and a health charity.
All were mature adults and there was an equal gender split (5 male, 5 female).
Group 3 (Thursday, n = 9), recruited through the University, had the broadest range of
ages (from young adult upwards) and mix of previous NHS involvement. Four people had
experience only as patients, although one of those described their previous experiences of
NHS care as ‘extensive’. One was a medic, one was an Allied Health Professional, one was
a mathematician engaged in research involving patient data, one had responsibility for
considering research protocols involving collaboration with the NHS, and one described
previous NHS involvement as “limited” but an active interest in the ethics of using data
for secondary purposes. Of the 9 participants, 4 were women and 5 were men.
Stage 1: Quantitative analysis
The quantitative data were used to address the first research question: Is there a difference
between what people prefer and what they are willing to accept? The analysis was
conducted in three parts and these are reported in this section:
i) Identification of the most/least preferred models
ii) Identification of the acceptable/non-acceptable models
iii)To what extent do respondents who express a low preference for a model display a
willingness to accept it?
Participants completed the questionnaire both before and after the round-table
discussion. Although not a central objective of this study, we felt it important to analyse
the morning and afternoon data separately in order to assess any aggregate changes in
preference/acceptability towards the four models. Previous studies using a similar focus
group/dialogue approach have shown that changes in opinion about consent in research
can be expected at the individual level, although not necessarily at the aggregate level.o
We found that a large proportion of respondents changed their views – only 8 people
(out of 28) did not change their answers at all. However, The Wilcoxon signed ranks test
(a non-parametric T-test which does not require normally distributed variables and is
suitable for the variable types) was used to assess whether there was a significant change
between morning and afternoon scores. None of the eight variables (Models 1–4,
preference and acceptability) were found to have statistically significant z scores; thus it is
possible to conclude that the afternoon discussion did not elicit a statistically significant
change on the aggregate attitudes of respondents, even though there were clearly some
shifts in perspective at the individual level.
There was no focus in our discussion on selection bias in particular and, as Hill et al.
speculate, the more specific nature of the information provided within their study might
account for the greater influence upon aggregate attitudes.p This might prove relevant to
the content of any information provided more generally about the adoption of opt out as a
model of consent. Although not statistically significant, the changes to preference and
acceptance results for the four models in the morning and afternoon sessions are discussed
in the sections that follow since they may inform future research.
i) What were the most/least preferred models?
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Figures 1 and 2 show the preference levels for each of the four models in the morning
and afternoon sessions. Broadly speaking, Models 2 and 3 emerged as most preferred;
they were more likely to be high preference (first and second preference combined) in
both the morning and afternoon sessions. Minor fluctuations in preference levels can be
observed between sessions. Model 2 was the most likely model to get first preference in
the morning; it lost a few allocations in the afternoon but gained more second preference
allocations, resulting in a consistently strong position overall. In contrast, Model 3
received an overwhelming majority of the second preference allocations in the morning
but there was a noticeable drop in the afternoon; in the afternoon session Model 3
emerged as the model most likely to be ranked first preference.
Model 1 was the least preferred model, with the majority of respondents ranking it as a
low preference (third or least). However, there is a marked increase in first preference
allocations in the afternoon session suggesting that for a few people (n = 3), the discussion
had a positive impact on their attitudes towards this model.
In line with the findings of some other studies,q there was limited preference for Model
4. The majority of respondents ranked it as a low preference (third or least), with most of
that majority selecting the lowest possible level of preference.r However, it was selected as
the most preferred option by more than a quarter of respondents. Of all the models,
Model 4 received the fewest fluctuations in preference ranking between morning and
afternoon sessions.
ii) What were the most/least acceptable models?
Looking at Figures 3 and 4, we see that Models 2 and 3 emerged as the most acceptable
models overall. Model 2 was slightly more acceptable in the morning (91% compared with
83%), but at the end of the afternoon Models 2 and 3 were deemed equally acceptable by
83% of participants. In the morning session, Model 1 was the least acceptable model, with
just over a quarter of respondents (28%) rating it as acceptable; in the afternoon, that
Figure 1 Levels in preference for Models 1–4 in the morning.
Taylor and Taylor Life Sciences, Society and Policy 2014, 10:15 Page 8 of 24
http://www.lsspjournal.com/content/10/1/15
figure increased to over half (52%). Model 4 was moderately acceptable in the morning
(56%), dropping to 52% in the afternoon. Four participants considered all four models to
be acceptable.
So, as was the case for levels of preference, it is the two ‘middle position’ models that
are most acceptable. Again, it is Model 1 that was viewed most negatively, with Model 4
receiving some support; interestingly Model 1 had the biggest increase in acceptability
after the discussion and information session.
iii)What proportion of those who expressed a negative preference towards each
model, would, nevertheless, accept it?
Figure 2 Levels in preference for Models 1–4 in the afternoon.
Figure 3 Acceptability for Models 1–4 in the morning.
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The next stage of the analysis was to assess whether there was a difference between that
which people prefer and that which they are willing to accept. Dealing first with Model 2,
which was ranked highest in terms of both preference and acceptability by the largest
proportion of people, three quarters (n = 6 of 8) of those who gave this model a low
preference score (i.e third preference or least preferred in the afternoon session) said that
they would be willing to accept it. Model 3 results were similar, with 60% (n = 3 out of 5) of
those who had given the model a low preference score saying that it would be acceptable.
As you move to the two extreme ends of the model spectrum, there is less willingness to
concede acceptability; for Model 1, only 14% (n = 3 out of 21) of low preference rankers
were willing to label the model acceptable and for Model 4, only 33% (n = 5 out of 15)s.
There was a small group of people (n = 5) who were unwilling to accept any model other
than that which they ranked as their first preference. This was observed across all four
models in the morning sessions. However, at the end of the afternoon session, two of these
people revised their responses to accept more than one model. This left three people only
willing to accept his or her most preferred model and in two of these cases it was Model 1.
Both of these people were in Group 2 (consisting of people with primary care involvement).
Summary
The key findings of Stage 1 of the analysis may be summarised as follows:
i) Model 1 is the least preferred model and it is the least acceptable model.
ii) Models 2 and 3 are the most preferred and the most acceptable models.
iii)Very few people (n = 3) were only willing to accept their most preferred model at
the conclusion of the session.
iv) Low preference for a model does not necessarily entail unwillingness to accept it.
Importantly, as with other studies there was no consistently preferred model of consent.
For the vast majority of people, the range of models of consent that each individual
Figure 4 Acceptability for Models 1–4 in the afternoon.
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considered to be potentially acceptable extended beyond the consent model that they
considered to be most preferable. There were only three people at the end of the
afternoon who considered their first choice to be the only acceptable alternative and two
of these preferred Model 1. This underlines both the potential for broader agreement
regarding the acceptability of a consent model than has previously been reported but also
the importance of taking into account the conditions expressed as relevant to acceptability
when designing any regulatory regime. The conditions raised by participants as relevant
are discussed as part of the qualitative analysis below.
Stage 2: Qualitative analysis
Having addressed the first research question, let us move on to consider what might influence
whether people are willing to accept a different level of control to that which they prefer.
Associated with this second question is understanding what conditions, if any, influence the
acceptability of different trade-offs between privacy and access to confidential patient data for
health research purposes. From the discussion of these conditions in the focus groups, 3 main
themes were identified, which are broken down into subthemes as shown in Table 2.
1) Appropriateness of access
Several people had concerns relating to the appropriateness of access that might be listed
under three discrete headings. It is important to underline that concerns relating to the
appropriateness of access appeared to be general concerns irrespective of the model of
consent adopted. Nevertheless, if an individual’s data are to be used without explicit
consent, then it seemed to be considered particularly important that these concerns were
addressed through appropriate safeguards. The concerns spontaneously expressed by
members of the focus groups could be said to relate to:
a) Security and Confidentiality
b) Detrimental Use
c) Commercialisation
1a. security and confidentiality Some people expressed the concern that the disclosure
of confidential patient data for research purposes may pose a risk to the security and
confidentiality of that data. For at least one person that concern was associated with the
disclosure of identifiers (including name and address) and other demographic data rather
than clinical data:
Table 2 Conditions influencing the acceptability of different trade-offs between privacy
and access to confidential patient data for health research purposes
Theme Sub-theme
1. Appropriateness of access 1a. Security and confidentiality
1b. Detrimental Use
1c. Commercialisation
2. Safeguards 2a. Opt-out
2b. Transparency
2c. Independent Overview
3. Sensitivity of data
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“my identity theft and attacking bank accounts and that sort of thing, that is my
concern, not my health data”. [TH2, Group 3]
Another pointed to the poor record of data security in the recent past as a cause for
concern if more identifiable data were to be used for health research purposes:
“Government departments, including the NHS, have got a pretty poor record for
securing personally identifiable information”. [TH7, Group 3]
Concerns about security and confidentiality were not, however, restricted to technical
questions around the prevention of unintentional loss or disclosure. There was also a
concern that people who were authorised to have access to data might find out things
about particular individuals. It was considered important that research was carried out by
somebody owing a duty of confidentiality:
“We are talking about data that is only going to researchers. These researchers inherit a
duty of confidentiality by dealing with this. If it was being passed on to a third party
who did not have a duty of confidentiality under the NHS, then that would be very
different”. [TH7, Group 3]
However, notwithstanding this duty of confidence, any possibility that researchers might know
the data-subjects personally was considered significant. It led one individual to remark that
“I think that people employed by an organisation that do that sort of work should
have the option to opt out, because they have the potential for their colleagues to be
handling very personal information about them” .[TU3, Group 1]
In response, another member of the group remarked that they might also be handling
“information about their neighbour [or] their family” [TU6, Group 1] and a similar
opportunity to opt out should be afforded anyone who personally knows somebody that
might be handling such data. This exchange queries the extent to which even perfect
security could fully address concerns about confidentiality when it is the knowing itself –
rather than the onward disclosure or loss of data - that is the concern. This concern was
obviously related in particular to data that was held in an identifiable form.
1b. Detrimental use: stigmatisation, discrimination and privacy intrusion A
number of concerns were expressed about purposes that might be considered detrimental
to the individual’s interests. While discussion was specifically about health research access
to PCD participants nonetheless felt compelled to express concerns about data being used
for other purposes:
“I personally don’t have any problems with my health care data being used for the
good of healthcare research or the benefit of healthcare but, like I said earlier, I do
worry about it straying off into commercial areas, insurance … [Interrupted by loud
and general agreement] …. [someone] mentioned military [research] earlier but I
think a much bigger risk of the abuse of data is by people in the insurance industry.
[TU3, Group 1]
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Similarly, there were concerns expressed over potential access by employers:
“If the results or the records on mental health are say passed on to a prospective
employer, you know there may be things that you don’t want to be known in there
that can mar your progress really if you get stigmatised” [W9, Group 2]
While it was recognised that access to an employer was unlikely to be granted for the
purposes of health research, it was noted that insurance companies employ researchers
and the definition of ‘health research’ is ambiguous. Concerns in this area were not
restricted to the disclosure of identifiable data and reservations associated with the
disclosure of even anonymised data have also been reported in similar studies.t There is a
concern that research results, even if reported at the level of the group, might have
consequences for individuals:
“Even if it is identifiable of a group, it could be, one could see particular dangers, a
religious group for example, or an ethnic group, that could present problems and certainly
we’ve had this in this past and, again, it is not just a question of what governments might
do towards part of its population, like in Nazi Germany they used their doctors and
health service there as part of the persecution of minorities [W7, Group 2]
Although concerns were associated with the use of data in anonymised form, most
frequent mention was made of risks to individuals if identifiable data was disclosed. The
risks were not only in relation to the possibility of discrimination or stigmatisation but
also just the possibility of intrusive direct marketing:
“[T]he main concern that I have is that eventually it is going to be used for marketing
purposes, and I think a lot of people think that as well you know that, it goes along the
line that your private information, I mean, with the NHS having that vast amount of
information, that eventually it will be used for marketing purposes” [W2, Group 2]
Comments resonated strongly with the finding of another study that “any linking
resulting in the individual being targeted with specific messages prompts discomfort and
resistance.”u For some, the concerns associated with marketing and other commercial use
of the data were associated with the privatisation of the health service:
“A lot of people would say, it is not necessarily my view, but a lot of people would say that
the whole of the health service is well on its way to being privatised and put into private
hands. It gives you a lot less confidence that any kind of data is going to be kept sacred if
you like and not released to private companies” [W1, Group 2]
The concerns associated with commercialisation were not just related to the economic
risks to which an individual might be exposed due to stratification of groups and direct
marketing. Concerns were also expressed around the commercialisation and commodifi-
cation of data more generally. People were generally happy for data to be used for the
purposes of improving the health of others but not providing individuals or groups with a
financial advantage.
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1c. Commercialisation Opposition to the commodification of data provided for ‘the
common interest’ was strongly expressed. This is consistent with the findings of other
studies. Hill et al. reported following their meta-study “there was apprehension in many
studies that data would be sold for commercial profit, and this was generally seen as less
acceptable, commanding a higher requirement for informed consent”.v Discussion in
these focus groups strongly supported that conclusion:
“Facilitator: Are there any burning things that people think we’ve missed on the first
part of the discussion?
TU1: Selling data
TU8: Yes
TU1: Well we don’t want it.
TU8: No
Facilitator: What, under no circumstances should anybody be allowed to sell data?
TU1: No. [Group 1]
While most starkly expressed here, the sentiment was widely shared and extended for
some to financial benefit for the NHS itself. There was a concern with the ‘corrupting’
effect that the sale of data might have upon NHS values:
“absolutely, I think we have to be aware of the fact that the NHS is not an infallible
system. It is not a deity, it is nothing other than an organisation of human beings who
make mistakes and who are subject to corruption and who .. I mean I think it is enough
that we are talking about personally identifiable information, that is essentially private
and important to the people that it concerns, and if we then add the thing on top of it
that there is the possibility that they could make money out of us, I mean, granted we
all use lots of money that is the NHS’s money but I think that that would add just a
whole new spectrum of grey”. [TH4, Group 3]
Although some did seem more accepting of the idea that the NHS might profit (and use
the money to support health care) the monetisation of the data was still resisted by many:
“TH8; I think most people would be reticent at the idea of the NHS selling the data-set
TH3; absolutely
TH2; but, I would actually be happier with the NHS having the money than the
individuals, I think the NHS is heading for bankruptcy, you know, maybe not in our
lifetime, but it can’t continue at the rate it is and so actually this could be a little bit of
a sweetener, so you know, they still provide a free access health service for everybody,
regardless of any discriminations or anything, and if they pocket a little bit of money to
continue that and to continue to fund new treatment, then that is where I can see....
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TH8; an interesting idea and I can see that you could produce a justifying argument,
but I think more people would be tempted to opt out if you went down that line…
[general agreement]
TH8; … I mean, even me with my sort of “yeh, take the data, as long as it is
acceptable, get on with it”, I would be tempted to opt out on that basis” [Group 3]
The discussion in Group 3 did, however, also draw out the difficulties in clearly
distinguishing between ‘commercial’ and ‘non-commercial’ research in the health sector.
It was recognised that “even therapeutic research are of commercial interest” [TH8,
Group 3] and some of the advantages of being able to draw upon commercial funds to
support health research were recognised:
“TH2; I think there is distinction as well between the commercial uses that you are
talking about there. So, I would whole heartedly agree with that, I wouldn’t want
anybody outside of the health sector looking at any of my identifiable data, so insurance
companies, banks, I don’t know, car loan people, but when you talk about the
commercial side of healthcare, I think there is a distinct difference between smith-kline
beecham and whatever, that although they are a commercial run company, I would
imagine an awful lot of the treatments that are provided on the NHS wouldn’t be there
if they hadn’t been supported in some form, so actually I think to separate commercial
and non commercial research for health purposes I don’t see how that is ever going to be
clear because it is ‘You scratch my back, I’ll scratch yours’
TH8; it is not black and white is it, it is a whole spectrum of greys in there too” [Group 3]
This demonstrates the subtly of view recognised by members of the public and an
appreciation of the complexity of the situation: Participants were aware of the value that
commercial partnerships might bring, but nonetheless remained extremely wary of PCD
being “sold” to such partners. The strength of feeling expressed would suggest that, while
people recognise it to be difficult to always point to bright-line distinctions, it is an area in
which public trust is extremely fragile.
2. Safeguards to protect people from risks?
In response to the concerns expressed around inappropriate use of data there were a
number of safeguards suggested. Trust that effective safeguards are able to prevent
inappropriate uses of data would seem to be crucial to the acceptability of lower levels of
individual control than preferred. A key safeguard appeared to be the option of individual
opt out. The opinions expressed on the issue of opt out were also expressed in particularly
strong terms.
2a. Opt out One participant said:
“I put [Model One: No Explicit Consent and No Opt Out] as number four because the
thought of not being able to opt out under any circumstances horrified me” [TH6, Group 3]
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This view did not appear to be significantly influenced by the possibility of independent
review by an independent body such as an ethics committee:
“Facilitator: How comfortable are you in devolving responsibility for the decisions
about your data to the ethics committee? Would it sway your opinion if they were, in
your mind, properly constituted?
TU3: If they are properly constituted, then yes it would sway my opinion but I still
would never ever be able to go for, or to feel comfortable with, a system in which I had
no control whatsoever. I would still want the right to protest and object and say “no”.
TU6: That’s my feeling exactly
TU3: I mean 99 times out of 100 I would probably not feel strongly enough
TU6: Yes, to object
TU3: but I still want to have that security that if there was something which I felt
really strongly about, there was a due legal process which I could go through to say
‘no you are not having my data’” [Group 1]
People wanted to be able to opt out if their data was to be used to support particular types
of research activity that they did not accept. In contrast to the findings of Hill et al.,w
reasons cited for possible opt out did include religious, moral and ethical views:
“You could you have it written in your notes, your record, that you would not allow it
for religious reasons, moral reasons, etc. etc. and that is written in to your notes. And
anything else that you want to” [TU9, Group 1]
Also,
“Facilitator: I don’t think we have example yet of a person being able to opt out for
any reason that they consider to be reasonable?
TU1: military research
TU8: and selling
TU9: so moral grounds
TU1: yes moral grounds. we all have different morals and ideas about what is ethical
and unethical” [Group 3]
Although it was recognised that unacceptable uses of data were not likely to be the primary
intent of any move to improve research access there was concern with “mission creep” [TU1,
Group 1]. This concern was particularly acute even if ‘opt out’ was permitted:
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“the problem is that you don’t know what is going to happen in the future. So you
don’t know if you want to object” [TU3, Group 1].
An important response to such concern was seen to be transparency.
2b. Transparency Other studies have similarly found that, alongside common courtesy,
being provided with information about what is done with information is recognised to be
an important prerequisite of effective exercise of any right to opt out.x How people were
to be provided with information about the purposes for which data was to be used was
suggested by one participant to be the “fundamental question”:
“[H]ow research is being conducted, what care is being taken to protect their data and
how that data is being used maybe for their own clinical treatment but also for future
clinical treatment for 20, 50,100 years. I think that is an important point, if we can solve
that question easily, then subsequent questions become quite easy to achieve. It just so
happens that this first one is incredibly hard”. [TH3, Group 3]
The size of the challenge was consistently recognised:
“Again you have the problem that there is so much information, so many hundreds of
thousands of different studies, how can you really make that a viable option other than
saying, be aware, you’re an NHS patient, your data may be used for research, the only
even viable way you could do that I think would be electronically and any more detail
than that via an internet link - something like that - but even then I would want to know
how realistic that could be for all studies to be out there. [TU3, Group 1]
Given the size of the challenge, and the fact that is was particularly acute in relation to spe-
cific groups, the suggestion was that we should ensure generic information is made clear to
all so that people can be signposted to more detailed information to consider at their con-
venience. Exactly how that generic level of information should be provided was considered to
vary between different groups with the overriding concern effective communication:
“If you are putting up written information, then what about people who can’t read?
What about people like drug users who may not interact with services? Again, the
homeless? Accessibility [of information] is a huge issue, especially for these groups, I
think it should be explained at the first instance, to people face to face, so you can
judge their understanding of what the opt out is and the threshold of any acceptable
opt out should be explained as well” [TH7, Group 3]
Particular efforts are going to have to be made in relation to particular groups to ensure
they are not left out if an opt out system is increasingly adopted:
“So therefore, that’s the group, the marginalised group in this kind of system, the opt
out system, the marginalised group are the people who, for whatever reason don’t
have the opportunity to learn about what is happening to their data and therefore
don’t have the opportunity to give an opinion on it even if their opinion is that they
do not want to be involved [TH4, Group 3]
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It was recognised that, even with the very best of intentions, and a flexible communica-
tion strategy capable of accommodating a diverse range of needs, there would be limits to
the extent to which all individuals could be effectively informed about all the very many
(research) purposes to which their data might be put. Indeed, the same person as quoted
immediately above suggested that if the goals of transparencies were realistically to be
achieved, then the practical difficulties associated with an opt out system might be as
great as with a system based on “explicit consent”:
“But is that not as difficult as getting explicit consent from every individual? I mean I
raised the point really to illustrate that opt out is very rarely actually informed, I
consider it not to be a form a consent and that is fine as long as accept that it is not a
form of consent. What would you do? Police that every single person visited the website,
or had access to a leaflet? I mean, even if they had access to a leaflet, you couldn’t
ensure that they had read it. I mean if every person in Sheffield received a leaflet about
how their data was being used, you have no way of knowing whether that went straight
in the recycling the second it came in the door. And, I think practically speaking,
informed opt out is as difficult and unrealistic as explicit opt in. [TH4, Group 3]
Recognising the limitations of transparency in practice, and the associated limits on
the extent to which individuals could use opt out (if available) to protect their own
interests, strengthened calls for an effective independent ‘watchdog’: a review group
capable of providing effective regulatory oversight and preventing inappropriate uses of
the information.
2c. ‘Watchdog’ or independent review group There was general agreement with the
suggestion that there should be an effective independent ‘watchdog’ or ‘independent
review group’ capable of protecting public interests. Interestingly, in two groups the
significance of lay review to such independence was clearly articulated:
“Facilitator: Who should be the guardians? Who should make the decisions about what,
who, and for what?
TU1: A non-governmental body
TU9: and non-NHS
TU1: This will be difficult group: a group that has no connection at all with industry,
commissioning groups, NHS, universities, anybody with a vested interest in using
data. How that would be achieved goodness knows” [Group 1]
In both of these groups participants spontaneously drew a parallel with the jury system
when considering the appropriate constitution of a review group: “12 lay people, like you
do on a jury”. One person went so far as to suggest that membership of such a review
group should be recognised to be a civic duty, as with jury service. However constituted,
it was recognised that:
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D7; “there would have to be some sort of body in charge of understanding, of
delineating at what point it is acceptable to not do these things, to not request
explicit consent from patients for identifiable information” [TH4, Group 3]
Interestingly, it was suggested that the value of the group might go beyond exercising a
quasi delegated function to protect the interests of those not in a position to protect their
own interests through opting out. It was suggested that the watchdog might provide more
rigorous control of data than an individual could achieve through opt out. Indeed, it was
suggested that the argument for such control might be particularly powerful if individuals
were not asked to explicit consent or even allowed to opt out of data collection:
“What would I think also convince me is the question that I raised earlier about the use of
the material and what would really be the pressure on the authorities, both the medical
authorities and the political authorities, to make sure that this material was used only for
health research purposes and only for the common good, and that would I think be a
much greater pressure than if you had a system whereby, either explicit consent [or some
kind of opt out system] where I can imagine the authorities sort of saying ‘you had your
chance to opt out – what are you complaining about?’ OK – we had to sell it to insurance
companies to cut the cost of research, you had your chance to get out of it, don’t complain
now”. [W7, Group 2]
“And I think if it wasn’t opt out, then the NHS the IC the watchdog, whoever, they would
have more responsibility to get that information out there so it is accessible and it is
understandable. It is not in a scientific paper, it is in a lay summary, so, ah! they did this
bit of research, that could have been my data, it might not have been but it could have
been” [TH5, Group 3]
3. Sensitivity of data
One set of concerns that are not easily aligned with the idea of inappropriate uses of data
or specific kinds of safeguard related to the use of particularly sensitive data. Several
people talked about data that they felt were particularly sensitive to them or to others
personally. Sometimes this was because the data related to a particular type of medical
condition, related for example to sexual or mental health:
“Isn’t that separate for different diseases. Like has already been said, you’ve got
different sensitivities about sexually transmitted diseases to those you do to the
common cold”. [TU3, Group 1]
“For myself there is a big difference between physical and mental health certainly my
physical health records, I have no problem with anybody doing any research on them at
all but I think that mental health particularly is a completely different ball game because
the repercussions of that coming back to haunt you later in life, and it doesn’t matter how
far back it goes into your childhood into your teens into your twenties, these things do have
a nasty habit, if they are brought back up, of becoming quite real again”. [W6, Group 2]
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Others noted instead the particularly sensitive nature of data that was intensely personal
in another way. For some this distinction fell along the boundary between primary and
secondary care settings:
“TU3: I sometimes look at it like this, I don’t have much worry about my secondary
care, my records about what has happened to me in hospital being shared with people
but when it goes into my primary care data I actually get a lot more sensitive and I am
much more tetchy about it, because there are things that I discuss with my GP, that I
really would not want anyone else to know about.
TU6: Absolutely
TU8: Yes” [Group 1]
For others, there were moments or events in their life that were so significant to them,
and the act of confiding the details in another had been such an acute act of trust, that
the thought that those details might be revealed – even in an anonymised form – was
intensely distressing:
“I certainly do have things in my medical records, from my very young years, which if I
thought anybody, ever, had access to, then I would be devastated. And that is whether
they have my name or not. I have still – 45 years later – I have problems when it is
brought to mind. The thought of somebody else going through that – whether they know
my name or not – I find it incredibly distressing”. [W6, Group 2]
Discussion and conclusions
This is, to our knowledge, the first study to focus specifically on the relationship between
preference and acceptability in the use of personal confidential data for health research. It
was designed as a small-scale pilot study and we must therefore be cautious before
extrapolating from the findings. The sample was small and the persons involved in the
research had either above average involvement with the NHS and/or above average
educational qualification. Furthermore, many of the participants drawn from the
university community were researchers themselves. Future work should be designed to
address these points of selection bias and ideally include participants with low or no
involvement in the NHS for comparative purposes.
The questionnaire was first completed after two presentations on the regulation of PCD
in the NHS and a consideration of the merits of different models of public interest
(involving different tradeoffs between individual control and research access). Previous
studies have suggested that a better understanding of the impediments posed to research
if explicit consent is insisted upon, would improve the acceptability of access without
consent.y One might speculate that this might explain why this group, with a relatively
high level of understanding of research in the NHS and the problems that researchers
would face, found ‘opt out’ to be a broadly acceptable solution even if it was not their first
preference. The possibility that this group might have been more supportive of opt out
models generally when compared with others does not undermine the central claim:
people typically considered models of consent other than their preferred model to be
Taylor and Taylor Life Sciences, Society and Policy 2014, 10:15 Page 20 of 24
http://www.lsspjournal.com/content/10/1/15
acceptable. The broadly expressed acceptance of alternatives to the first preference was
accompanied with concerns that adequate safeguards be put in place to protect trust that
identifiable, and for some also anonymised, data were not going to be used in ways that
people did not consider acceptable. It has been suggested by other studies that people are
more likely to accept alternatives to explicit consent if they are confident that alternative
mechanisms of control are going to ensure that data is used by persons, and for purposes,
that they trust and accept as reasonablez.
Our key finding is that people are typically willing to accept models of consent other
than that which they would prefer. This should be taken into account when designing
future studies to test the acceptability of different consent models. Asking people to
select between different alternative models might yield information about which models
people would prefer (and past evidence is that this is actually quite fragmented as a
preference) but this does not directly provide any reliable indicator of acceptability.
However, if acceptability is a concern, then we should pay attention to those factors
that people have expressed as relevant to their acceptance of different models of
consent, including those models that provide lower levels of individual control than
they would ideally prefer. These include security and confidentiality, controls over det-
rimental use and commercialisation, adequate transparency, existence of a independent
‘watchdog’, and the ability to object, particularly to any processing considered to be
inappropriate or particularly sensitive.
This is important because England and Wales appear to be moving toward the use of
PCD for health research purposes without explicit patient consent. This study suggests
that the political commitmentaa to respect opt out in relation to health research access to
PCD is consistent with not only what people prefer but also what they would consider to
be acceptable. We would suggest that continuing to respect opt out may be an important
part of public acceptability of any operative consent model.
Given that other studies have consistently reported a fragmented picture regarding
public preferences for particular models of consent (e.g. broad opt in, specific opt in, opt
out, etc.) it is significant that we have found a difference between what people would
indicate to be their preferred model (if given only one choice) and what they would be
willing to accept. Particularly, if they recognise and accept certain reasons for adopting an
alternative other than their first choice. The results suggest that it might be possible to
gather a much broader alliance of support around particular models if one focuses upon
acceptability rather than preference.
Reasonable acceptability does, however, depend upon persons having access to the
reasons for the alternatives. We must get better at explaining to people why they might
have reason to accept models other than their preferred model in relevant circumstances.
Assurance that these reasons are sufficient to lead somebody to accept a lower level of
control over their data than they would ideally prefer depends in part upon a trust that
adequate alternative safeguards exist to address their concerns and to protect their
interests.
The willingness to accept any particular trade-off is informed by an understanding of
the controls that exist around the access and use of the information. Concerns were
expressed around the security and confidentiality of the data, the fact that it is not used to
an individual’s detriment, in either identifiable form or as a result of research conducted
at the level of the group; and the commercialisation of data.
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The safeguards identified as necessary to address such concerns included adequate
transparency, a strong independent watchdog capable of protecting an individual’s
interests and ensuring that data was only used ‘in the public interest’, and the opportunity
to opt out of particular processing if the purposes, or the data accessed, are considered to
be particularly sensitive by an individual. The possibility of overriding an opt out was
considered, and it was recognized that it might be necessary in some circumstances, but
people were of the opinion that it should be a rare occurrence given the fact that people
have different sensitivities around particular types and uses of data.
Endnotes
aThe term is being used here as defined by The Information Governance Review
Information: To Share or not to Share (March, 2013), p130: “This term describes personal
information about identified or identifiable individuals, which should be kept private or
secret. For the purposes of this review ‘Personal’ includes the DPA definition of personal
data, but it is adapted to include dead as well as living people and ‘confidential’ includes
both information ‘given in confidence’ and ‘that which is owed a duty of confidence’ and is
adapted to include ‘sensitive’ as defined in the Data Protection Act”.
bSee s259 Health and Social Care Act 2012. For additional comment on these
changes see Grace and Taylor (2012).
cMadlen Davies, ‘Patients to be given “veto” over their data being shared from GP
records’ pulsetoday (online), 26 April 2013. It has recently been announced that legal
Directions are to give legal force to this right to opt out. See statement of Dr Dan Poulter,
Under Secretary of State for Health, to the House of Commons, Hansard HC Deb 10
March 2014, col 134.
dResearch Capability Programme Team ‘Summary of Responses to the Consultation on
the Additional Uses of Patient Data’ (Department of Health, 27th November 2009); Stone
et al. (2005); Robling et al. (2004) For similar conclusions in New Zealand, see Whiddett et
al. 2006; for the USA, see Damschroder et al. 2007.
eResearch Capability Programme Team, Department of Health ‘Summary of Responses
to the Consultation on the Additional Uses of Patient Data’ (Department of Health,
27th November 2009), p.6.
fHill et al. (2013).
gHill et al. (2013), p2.
hibid.
iHill et al. (2013), p7.
jSee the care.data programme for an example of a significant national programme to
extract PCD from health records without explicit patient consent. http://www.england.
nhs.uk/ourwork/tsd/care-data/. For reporting of an upcoming publicity campaign see
http://www.ehi.co.uk/news/EHI/8961/%C2%A31m-national-leaflet-drop-on-care.data.
k
‘Public and Patient Involvement’ (PPI) is a term that is used variously to describe
engagement with members of patient and public communities in the decisions about
health care and research. See description of PPI in House of Commons Health Committee,
Patient and Public Involvement in the NHS, (Vol.1) (HC278-1), Ch.2. In this case, participants
were approached through membership of specific patient or PPI groups and membership of
relevant groups was described by participants in their own words at the beginning of the
workshop.
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lParticipants were told that, for the purposes of completing the questionnaire, they
should assume ‘sufficiency’ was to be assessed in a way that they agreed was appropriate.
mIBM Statistical Package for the Social Sciences (SPSS) version 17 for Windows.
nNVivo 10 for Windows, QSR International.
oWillison et al. (2008). This contrasts with the findings of Hill et al. (2013) where some
shift in aggregate opinion was found.
pHill et al. (2013), p7.
qe.g. Research Capability Programme Team, Department of Health ‘Summary of Responses
to the Consultation on the Additional Uses of Patient Data’ (Department of Health, 27th No-
vember 2009), p.6; Willison et al. (2008) where “Four percent of respondents thought infor-
mation from their paper medical record should not be used at all for research, 32% thought
permission should be obtained for each use, 29% supported broad consent, 24% supported
notification and opt out, and 11% felt no need for notification or consent” (p706).
rIn light of the difference in views on use of identifiable data without consent by pub-
lic, patients, and researchers reported in the summary of responses to the consultation
on the additional uses of patient data (ibid) this finding may reflect the particular com-
position of the focus groups and their relatively high levels of prior involvement with
the NHS. This could usefully be the subject of further research.
sThe Fisher’s Exact test was used to test whether there were any statistically significant rela-
tionships between preference and acceptability variables (this is appropriate when samples
sizes are small and cells commonly contain fewer than 5 cases); Cramer’s V was deemed ap-
propriate to measure the strength of association. However, of the 8 cross-tabulations (one for
each of the four models in both the morning and afternoon), only 4 statistically significant re-
lationships were found (p < 0.005), all of which related to Models 1 and 4 (AM and PM). We
can tentatively conclude that there is a significant, moderate association between preference
and acceptability for Models 1 and 4; people who ranked these as non-preferable models are
also significantly more likely to find them unacceptable (and vice versa). However, here the
lack of a statistically significant relationship between preference and acceptability for Models
2 and 3 show that there is a much more complex picture to be understood; here is where
the most interesting trade-offs between privacy and access to data are coming into play.
tResearch conducted in New Zealand found that “60% of respondents expressed some
reservations about sharing even anonymous information with people other than health
professionals. This result is similar to findings in the UK and Australia which identified that
many people desire some control over their data even if it is anonymous” Whiddett et al,
2006 However, compare Wellcome Trust, Summary Report of Qualitative Research into
Public Attitudes to Personal Data and Linking Personal Data (2013), page 13 [3.7].
uWellcome Trust, Summary Report of Qualitative Research into Public Attitudes to
Personal Data and Linking Personal Data (2013), page 13 [3.6].
vHill et al. (2013) p5.
wHill et al. (2013), p6.
xRobling et al. (2004), p106.
yHill et al. (2013).
zWillison et al. (2008) reported that support for research use of PCD “is dependent
on the intended uses and users of the data and on the safeguards applied”. p710; See
also, Damschroder et al. (2017).
aaSee n.3 above.
Taylor and Taylor Life Sciences, Society and Policy 2014, 10:15 Page 23 of 24
http://www.lsspjournal.com/content/10/1/15
Abbreviations
PCD: Personal confidential data.
Competing interests
Mark Taylor is currently the Establishing Chair of the Confidentiality Advisory Group for the Health Research Authority.
His authorship of this manuscript is in the capacity of a university academic. The content should not, in any way, be
understood to represent the views of, or by attributed to, the Confidentiality Advisory Group or the Health Research
Authority or any other group of which he is a member.
Author’s contributions
MT organised the focus groups, delivered presentations prior to the focus group discussion, sat in on and subsequently
transcribed the focus group discussion, thematically coded the discussion using NVIVO software and drafted the
introduction, conclusion and section on qualitative analysis. NT carried out the quantitative analysis and drafted the section
on quantitative analysis. She also thematically coded the focus group transcripts and contributed toward the re-drafting of
the entire piece following comments. Both authors read and approved the final manuscript.
Authors’ information
Mark Taylor is a Senior Lecturer in Law at the University of Sheffield and Deputy Director of the Sheffield Institute of
Biotechnology Law and Ethics.
Natasha Taylor is a Senior Research Fellow at the University of Huddersfield and has a particular interest and expertise
in research methods.
Acknowledgements
We would like to thank the participants in the focus groups. The Facilitator, Mr David Ardron, and the colleagues who
have kindly commented on drafts of this paper including, and most notably, Dr Liz Hill, Professor Don Willison, and
Dr Susan Wallace. We would also like to thank the two anonymous reviewers who provided excellent comments on
the original submission.
This research was carried out, and the manuscript drafted, while Mark Taylor was on study leave funded by the British
Academy as a mid-career Fellowship. The support of the British Academy is gratefully acknowledged.
Author details
1School of Law, Bartolomé House, The University of Sheffield, Winter Street, Sheffield S3 7ND, UK. 2School of Law, The
Business School, The University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK.
Received: 12 November 2013 Accepted: 27 May 2014
References
Crow, I, and N Semmens. 2008. Researching Criminology. McGraw-Hill: Maidenhead.
Damschroder, LJ, JL Pritts, MA Neblo, RJ Kalrickal, JW Creswell, and RA Hayward. 2007. Patients, privacy and trust:
Patients’ willingness to allow researchers to access their medical records’. Soc Sci Med 64: 223–235.
Grace, J, and MJ Taylor. 2012. Disclosure of confidential patient information and the duty to consult: The role of the
health and social care Information Centre. Med Law Rev. first published online March 29, 2013.
Hill, EM, EL Turner, R Martin, and JL Donovan. 2013. “Let’s get the best quality research we can”: public awareness and
acceptance of consent to use existing data in health research: a systematic review and qualitative study’. BMC Med
Res Methodol 13: 72.
House of Commons Health Committee, Patient and Public Involvement in the NHS, (HC 2006-2007, 278-I).
Robling, MR, K Hood, H Houston, R Pill, J Fay, and HM Evans. 2004. Public attitudes towards the use of primary care
patient record data in medical research without consent: a qualitative study’. J Med Ethics 30: 104–109.
Stone, MA, AS Redsell, JT Ling, and AD Hay. 2005. Sharing Patient Data: Competing demands of privacy, trust and
research in primary care. Br J Gen Pract 783–789.
Whiddett, R, I Hunter, J Englebrecht, and J Handy. 2006. Patient's attitudes towards sharing their health information. Int
J Med Informatics 75: 530–541.
Willison, DJ, M Swinton, L Schwartz, J Abelson, C Charles, D Northrup, J Cheng, and L Thabane. 2008. Alternatives to
project-specific consent for access to personal information for health research: Insights from a public dialogue’.
BMC Med Ethics 9: 18.
doi:10.1186/s40504-014-0015-6
Cite this article as: Taylor and Taylor: Health research access to personal confidential data in England and Wales:
assessing any gap in public attitude between preferable and acceptable models of consent. Life Sciences, Society
and Policy 2014 10:15.
Taylor and Taylor Life Sciences, Society and Policy 2014, 10:15 Page 24 of 24
http://www.lsspjournal.com/content/10/1/15
